BridgeBio Pharma announced that it will buy Eidos Therapeutics in a cash and stock deal worth $2.83 billion, with the transaction expected to be finalized by the first quarter of next year. Eidos is developing the ATTR cardiomyopathy and polyneuropathy treatment acoramidis.
BridgeBio acquires Eidos in $2.8B cash, stock deal
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.